Regencell Bioscience/RGC

$7.79

-2.62%
-
1D1W1MYTD1YMAX

About Regencell Bioscience

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Ticker
RGC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
-
Employees
12
Headquarters
Null, Hong Kong

RGC Metrics

BasicAdvanced
$104.1M
Market cap
-
P/E ratio
-$0.59
EPS
-
Beta
-
Dividend rate

RGC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 22
QoQ growth
Revenue
$0
-
Net income
$-3.8M
8.57%
Profit margin
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Regencell Bioscience stock

Buy or sell Regencell Bioscience stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing